Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor

[Image: see text] For a subpopulation of acute myeloid leukemia (AML) patients, the mutationally activated tyrosine kinase FLT3, has emerged as a promising target for therapy. The development of drug resistance due to mutation is a growing concern for mutant FLT3 inhibitors, such as PKC412, Quizarti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ACS Med Chem Lett
Glavni autori: Hatcher, John M., Weisberg, Ellen, Sim, Taebo, Stone, Richard M., Liu, Suiyang, Griffin, James D., Gray, Nathanael S.
Format: Artigo
Jezik:Inglês
Izdano: American Chemical Society 2016
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4867484/
https://ncbi.nlm.nih.gov/pubmed/27190596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00498
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items